GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DongKook Pharmaceutical Co Ltd (XKRX:086450) » Definitions » Revenue

DongKook Pharmaceutical Co (XKRX:086450) Revenue : ₩789,114 Mil (TTM As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is DongKook Pharmaceutical Co Revenue?

DongKook Pharmaceutical Co's revenue for the three months ended in Sep. 2024 was ₩200,879 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ₩789,114 Mil. DongKook Pharmaceutical Co's Revenue per Share for the three months ended in Sep. 2024 was ₩4,486.70. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₩17,638.60.

Warning Sign:

DongKook Pharmaceutical Co Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of DongKook Pharmaceutical Co was 11.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 9.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 28.60% per year. During the past 10 years, the average Revenue per Share Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, DongKook Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 90.00% per year. The lowest was -32.60% per year. And the median was 13.65% per year.


DongKook Pharmaceutical Co Revenue Historical Data

The historical data trend for DongKook Pharmaceutical Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DongKook Pharmaceutical Co Revenue Chart

DongKook Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 482,280.35 559,103.46 594,193.12 661,647.49 730,993.60

DongKook Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 176,437.67 187,876.23 196,820.89 203,537.92 200,878.56

Competitive Comparison of DongKook Pharmaceutical Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, DongKook Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DongKook Pharmaceutical Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DongKook Pharmaceutical Co's Revenue distribution charts can be found below:

* The bar in red indicates where DongKook Pharmaceutical Co's Revenue falls into.



DongKook Pharmaceutical Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩789,114 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DongKook Pharmaceutical Co  (XKRX:086450) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


DongKook Pharmaceutical Co Revenue Related Terms

Thank you for viewing the detailed overview of DongKook Pharmaceutical Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


DongKook Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Dongkook Building 997-8 Daechi 3-dong, Kangnam-gu, Seoul, KOR, 135-502
DongKook Pharmaceutical Co Ltd is a part of the healthcare industry based in Korea. Being a pharmaceutical company, its activities are focused on the research and development of drugs. The company produces superior medicines used favorably by consumers such as Madecassol, which is a drug for wounds and Oramedy, which is a drug for treating stomatitis. It also owns a prefilled syringe system in its second factory, through which it produces various kinds of ultramodern injection agents.

DongKook Pharmaceutical Co Headlines

No Headlines